18 May
2021

India resists calls to use existing compulsory licensing powers for covid drugs

India’s government has stated its unwillingness to bypass patents for covid-19-approved drugs, despite its advocacy of a TRIPS suspension and growing political pressure for compulsory licensing

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth